KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Treasury Shares (2016 - 2025)

Historic Treasury Shares for CRISPR Therapeutics AG (CRSP) over the last 8 years, with Q4 2025 value amounting to $60000.0.

  • CRISPR Therapeutics AG's Treasury Shares fell 322.58% to $60000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $60000.0, marking a year-over-year decrease of 322.58%. This contributed to the annual value of $60000.0 for FY2025, which is 322.58% down from last year.
  • CRISPR Therapeutics AG's Treasury Shares amounted to $115316.0 in Q4 2025, which was down 3229.29% from $125316.0 recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Treasury Shares ranged from a high of $195316.0 in Q1 2021 and a low of $115316.0 during Q4 2025
  • For the 5-year period, CRISPR Therapeutics AG's Treasury Shares averaged around $172316.0, with its median value being $180316.0 (2021).
  • Per our database at Business Quant, CRISPR Therapeutics AG's Treasury Shares changed by 0.0% in 2021 and then crashed by 322.58% in 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Treasury Shares (Quarter) stood at $63000.0 in 2021, then changed by 0.0% to $63000.0 in 2022, then fell by 1.59% to $62000.0 in 2023, then changed by 0.0% to $62000.0 in 2024, then dropped by 3.23% to $60000.0 in 2025.
  • Its Treasury Shares was $60000.0 in Q4 2025, compared to $60000.0 in Q3 2025 and $62000.0 in Q2 2025.